Following a new diagnosis, one of the first questions most people ask their medical team is, ‘What is the survival rate for thyroid cancer?’ It is a natural response to seeking clarity during a stressful time. The reassuring news is that thyroid cancer generally has one of the highest survival profiles of any malignancy.
However, a single statistic does not look at your individual health history. Your actual outlook depends entirely on a few key factors, including your age when diagnosed, the specific type of thyroid cells involved, and whether the disease has spread.
What Is the Overall Thyroid Cancer Survival Rate?
According to a review conducted in the US on thyroid cancer, the overall 5-year thyroid cancer survival rate across all types and stages combined sits at an incredibly reassuring 98.5% (Boucai, Zafereo and Cabanillas, 2024). This means that the vast majority of individuals diagnosed with this disease go on to live long, healthy lives.
To give you the most accurate picture, oncologists rely on “relative survival rates”. This metric compares people with a specific type and stage of thyroid cancer to the general population. For example, a 5-year relative survival rate of 99% means that a person with this cancer is, on average, 99% as likely to live for at least 5 years after diagnosis as someone who does not have this cancer.
Thyroid Cancer Survival Rate by Age
Age plays a uniquely critical role in thyroid oncology. Unlike almost any other type of cancer, the staging system for differentiated thyroid cancer (papillary and follicular) changes explicitly based on whether you are younger or older than 55 years old (Lamartina et al., 2018).
The thyroid cancer survival rate by age reflects the following trends:
- Patients Under 55: Younger individuals have an exceptionally robust prognosis. Even if the cancer has spread to nearby lymph nodes in the neck, the 5-year survival rate remains near 100% (American Cancer Society, 2025). The disease in younger populations tends to be highly responsive to standard treatments like surgery and radioactive iodine.
- Patients 55 and Older: For older individuals, the disease can sometimes behave more aggressively, and the risk of recurrence increases slightly (Sapuppo, Tavarelli and Pellegriti, 2020). While survival rates remain remarkably high, the staging guidelines expand to help medical teams monitor and treat older patients with greater vigilance (Lamartina et al., 2018).
The data from the MSKCC multicentre study (“Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?”) are presented in a clean table format. This study measured the 10-Year Disease-Specific Survival (DSS), meaning the percentage of patients who survived their thyroid cancer over a 10-year period, broken down by age cutoffs at diagnosis.
| Age at Diagnosis | 10-Year Survival Rate of Thyroid Cancer |
| Under 30 | 99.3% |
| Under 35 | 99.6% |
| Under 40 | 99.7% |
| Under 45 | 99.3% |
| Under 50 | 99.3% |
| Under 55 | 99.1% |
| Under 60 | 98.6% |
| Under 65 | 98.4% |
| Under 70 | 97.8% |
| Age 70 and over | 71.2% |
Survival Rates by Type and Stage
Thyroid cancer is categorised into four main types based on how the cells look under a microscope. The stage, categorised as localised, regional, or distant by medical databases, indicates how far those cells have travelled.
1. Papillary and Follicular (Differentiated) Thyroid Cancer
These are the most common types, accounting for over 90% of all thyroid cancer cases. (American Cancer Society, 2025; Medical News Today, 2023). They grow slowly and are highly treatable.
- Localised (confined to the thyroid): The 5-year survival rate is greater than 99.5% (American Cancer Society, 2025; Medical News Today, 2023)
- Regional (Spread to nearby lymph nodes): The 5-year survival rate remains excellent at roughly 98% (American Cancer Society, 2025; Medical News Today, 2023)
- Distant (Metastatic disease): If the cancer spreads to distant sites like the lungs or bones, the metastatic thyroid cancer survival rate drops to approximately 55% to 75%. However, modern targeted therapies are steadily improving these long-term numbers (American Cancer Society, 2025; Medical News Today, 2023)
2. Medullary Thyroid Cancer
This type develops from the C-cells of the thyroid gland and behaves differently than differentiated types.
- Localized: The 5-year survival rate is close to 99% (American Cancer Society, 2025; Medical News Today, 2023)
- Regional: The survival rate is approximately 94% (American Cancer Society, 2025; Medical News Today, 2023)
- Distant: If it spreads to distant organs, the survival rate is 50% (American Cancer Society, 2025; Medical News Today, 2023)
3. Anaplastic Thyroid Cancer
This is a rare and highly aggressive form of thyroid cancer, making up less than 1% of cases. It typically occurs in older adults.
Because it grows and spreads very rapidly, the anaplastic thyroid cancer survival rate is lower, with an overall 5-year survival rate hovering around 4% to 45% (Medical News Today, 2023). However, immediate and aggressive treatment strategies, including newly developed targeted genetic therapies, are offering fresh hope and extending survival timelines for these patients.
Key Factors That Influence Your Outlook
While statistics provide a helpful baseline, they are based on data from thousands of patients over several years. Your individual journey is influenced by personalised factors that statistics cannot fully capture:
- Early Detection: Catching a nodule early, before it grows large enough to break through the thyroid capsule, ensures the highest likelihood of a complete cure.
- Surgical Precision: Undergoing an optimal initial surgery to cleanly remove the tumour reduces the risk of local recurrence.
- Genetic Mutations: Identifying specific genetic markers, such as BRAF or RET mutations, allows oncologists to use highly precise targeted therapies if standard treatments fall short.
CTA: Worried about yours or a loved one’s thyroid cancer treatment? Speak to Dr Amit
Looking to the Future
The numbers surrounding thyroid cancer are overwhelmingly positive. For the vast majority of patients, life after treatment returns to a completely normal routine, requiring nothing more than a daily hormone tablet and routine check-ups.
Because every diagnosis is unique, these statistics should serve as a source of reassurance rather than a definitive roadmap. Partnering with a dedicated specialist ensures you receive a personalised strategy tailored precisely to your health profile.
Take the Next Step
If you or a loved one needs clarity on a thyroid diagnosis, seeking expert guidance is the best way to move forward with peace of mind. Dr. Amit Chakraborty and his team specialise in comprehensive thyroid care, offering accurate staging and cutting-edge treatment options.
Book a consultation at Dr Amit’s Cancer Care. Call or WhatsApp: +91 86577 17988
Disclaimer: This blog is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist or healthcare professional regarding diagnosis and treatment decisions.
References
American Cancer Society, 2025. Thyroid Cancer Survival Rates, by Type and Stage.
Boucai, L., Zafereo, M. and Cabanillas, M.E., 2024. Thyroid cancer: a review. Jama, 331(5), pp. Pp.425-435.
Ganly, I., Nixon, I.J., Wang, L.Y., Palmer, F.L., Patel, S.G., Shaha, A.R., Tuttle, R.M. and Shah, J.P., 2015. Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It? Thyroid, 25(10), pp.1106–1114.
Lamartina, L., Grani, G., Durante, C. and Filetti, S., 2018. 8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2). Endocrine-Related Cancer, 25(3), pp. L7–L11. Available at: https://doi.org/10.1530/ERC-17-0453.
Medical News Today, 2023. Thyroid cancer prognosis by age, stage, and more. Reviewed by Medical News Today Editorial Guidelines.
Sapuppo, G., Tavarelli, M. and Pellegriti, G., 2020. The new AJCC/TNM Staging System (VIII ed.) in papillary thyroid cancer: Clinical and molecular impact on overall and recurrence-free survival. Annals of Translational Medicine, 8(13), p. 834. Available at: https://doi.org/10.21037/atm-20-2187.
Aug 20, 2024 
